Type 2 diabetes
Conditions
Interventions
alogliptin
glimepiride
Sponsors
Divison of Diabetes and Metabolism,Itabashi Hospital, Nihon University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Type 2 diabtes 2)No change in therapy with oral antidiabetes agent at least 3 months 3)HbA1c: 7.0-8.5%,,treated with metformin 4)age: 20 - 75 years 5)made a written informed consent 6))patients who do not have an allergy to test meal
Exclusion criteria
Exclusion criteria: 1)iabets mellitus due to glucagon-producing tumor 2) patients:the medicine is changed within the last three months 3) Type 1 diabtes,HbA1c: higher than 10.5%,patients who require hospitalization for high blood glucose or diabetic ketoasidosis 4) patients treated with Dpp-4 inhibitor, sulfonylurea or insulin injection 5)patients with nephrotic syndrome 6) hypersensitivity to drugs on this study 7) renal dysfunction (1.3 and 1.2 mg/dL or more for male and female, respectively) 8)hepatitis (AST,ALT: three folds higher than baseline), 9) pregnancy, possibly pregnant woman 10) patients who are inadequate to enter this study due to the other reasons by physician's judgments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c | — |
Secondary
| Measure | Time frame |
|---|---|
| blood glucose, plasma insulin,plasma glucagon | — |
Countries
Japan
Contacts
Public ContactSuguru Yamaguchi
Itabashi Hospital, Nihon University School of Medicine Divison of Diabetes and Metabolism
Outcome results
None listed